Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
LSTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.87 - $4.20
Previous CloseN/A
Volume45.87K
Average Volume (3M)43.05K
Market Cap
$22.87M
Enterprise Value$3.00M
Total Cash (Recent Filing)$25.83M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 18, 2025EPS Estimate
-0.65Last Dividend Ex-Date
Oct 28, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding8,598,204
10 Day Avg. Volume83,151
30 Day Avg. Volume43,051
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue1.50
Enterprise Value/Gross Profit3.28
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$23.50Price Target Upside773.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Lisata Therapeutics News
PremiumCompany Announcements
Lisata Therapeutics Secures U.S. Patent for Certepetide
PremiumCompany Announcements
Lisata Therapeutics Reveals Promising Phase 2 Trial Data
PremiumCompany Announcements
Lisata Therapeutics Advances Certepetide for Cancer TreatmentBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEncouraging preliminary results from Cohort B of the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma.
Strategic CollaborationExpanded strategic collaboration with GATC Health to de-risk and accelerate drug development.
Bears Say
Market CompetitionOverall disease control rate was 85.9% for certepetide vs. 61.9% for placebo, indicating strong competition in the market.
Options Prices
Currently, No data available
---
Ownership Overview
8.06% Insiders
3.65% Mutual Funds
2.66% Other Institutional Investors
82.56% Public Companies and
Individual Investors
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $1.87 and its highest was $4.20 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $22.87M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 22 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on May 08, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.53 by -$0.02.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics pays a Notavailable dividend of $0.31 which represents an annual dividend yield of N/A. See more information on Lisata Therapeutics dividends here
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -0.65.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 8,598,204 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.53. Following the earnings report the stock price went down -11.392%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in LSTA
Lisata Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.50 (773.61% Upside)
$23.50 (773.61% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.22%
12-Months-Change
Fundamentals
Return on Equity
-56.49%
Trailing 12-Months
Asset Growth
-39.92%
Trailing 12-Months
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
LSTA Company Deck
LSTA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial management improvements, despite some delays and challenges in strategic partnerships and trial enrollments. The company's focus on advancing Certepetide through various trials and securing regulatory designations indicates a strong strategic direction.Read More>LSTA Stock 12 Month Forecast
Average Price Target
$23.50
▲(773.61%Upside)
Technical Analysis
ProMIS Neurosciences
―
ImmunoPrecise Antibodies
―
BioAtla
―
Elevation Oncology
―
Jupiter Neurosciences, Inc.
―